1 “... in patients with BRAF mutation positive unresectable or metastatic melanoma who have received immunotherapy...”

2 “... in patients with BRAF mutation positive unresectable or metastatic melanoma who have received immunotherapy...”

3 “... vemurafenib for patients with BRAF (human gene that encodes a protein called B-Raf) mutation positive...”

4 “... vemurafenib for patients with BRAF (human gene that encodes a protein called B-Raf) mutation positive...”

5 “... of complete blood counts to monitor for heparin-induced thrombocytopenia in cardiac patients receiving...”

6 “... of complete blood counts to monitor for heparin-induced thrombocytopenia in cardiac patients receiving...”

7 “... of walking in patients with foot drop caused by various neurological conditions, but the effectiveness of FES...”

8 “...) with 27 patients and reported no statistically significant difference between the two modalities...”

9 “... of walking in patients with foot drop caused by various neurological conditions, but the effectiveness of FES...”

10 “...) with 27 patients and reported no statistically significant difference between the two modalities...”

11 “... results in improvement in body composition in patients with Prader-Willi syndrome and summarized evidence...”

12 “... results in improvement in body composition in patients with Prader-Willi syndrome and summarized evidence...”

13 “... the potential for increased expense on the part of the patient and/or third-party payers, evidence is needed...”

14 “... prophylaxis in patients undergoing total hip or knee replacement surgeries...”

15 “... prophylaxis in patients undergoing total hip or knee replacement surgeries...”

16

17

18 “...-based guidelines regarding the use of rituximab as maintenance therapy for patients with GPA and MPA...”

19 “... bowel preparation for patients undergoing elective colorectal procedures...”

20 “...-based guidelines regarding the use of rituximab as maintenance therapy for patients with GPA and MPA...”